Sunday (04.10.2026)

08:00 – 09:15

Room: Großer Saal

Scientific Session HL in Children and Adolescents

  • Jamie Flerlage
  • Christine Mauz-Körholz
  • 08:00–08:20

    Treatment Evolution in Pediatric Hodgkin Lymphoma: From Research to Real-World Impact

    • Maurizio Mascarin
  • 08:20–08:40

    Precision Medicine in Pediatric HL / Harmonized Pediatric HL Protocol in South Africa

    • Jennifer Geel
  • 08:40–08:55

    Abstract T071: The Genomic Landscape of Pediatric High-Risk Hodgkin Lymphoma: A Liquid Biopsy Study of COG AHOD1331

    • Lianna Marks
  • 08:55–09:15

    Abstract T072: Body-Size Normalisation of Metabolic Tumour Volume in Paediatric Hodgkin Lymphoma: Does MTV/BSA Improve Prognostic Stratification and Reclassify Smaller Children?

    • Claire Gowdy

08:00 – 10:00

Room: Ratsstube

Separate registration required Workshop Closed Workshop on Grassroot Initiative in Classic Hodgkin Lymphoma

  • Ranjana Advani
  • Peter Borchmann
  • Peter Omondi Oyiro

09:30 – 10:30

Room: Großer Saal

Satellite Symposium (by MSD Sharp & Dohme GmbH) New concepts for the treatment of B-cell lymphomas

  • Bastian von Tresckow
  • 09:30–10:00

    DLBCL – The current and future role of ADCs in the context of T-cell engaging therapies

    • Björn Chapuy
  • 10:00–10:30

    cHL – Treatment strategies for PD-1 inhibition in the relapsed / refractory setting

    • Bastian von Tresckow

10:45 – 12:00

Room: Großer Saal

Scientific Session Translating ctDNA into clinical routine

  • Sven Borchmann
  • Margaret Shipp
  • 10:45–11:05

    Circulating Tumor DNA: New insights from the SWOG S1826 study.

    • Margaret Shipp
  • 11:05–11:25

    Circulating Tumor DNA Analysis for Classification and MRD Assessment – Experience of the German Hodgkin Study Group

    • Sven Borchmann
  • 11:25–11:50

    Workshop Report

    • Christian Steidl
  • 11:50–12:00

    Abstract T048: A Reproducible Mutation- versus Copy-Number-Enriched Genomic Axis Underlies Molecular Subtypes of Classic Hodgkin Lymphoma

    • Cara Paulina Lange

12:15 – 13:30

Room: Großer Saal

Scientific Session Biology & Pathology

  • Wolfram Klapper
  • Christian Steidl
  • 12:15–12:35

    The Biology of HRS Cells

    • Ralf Küppers
  • 12:35–12:55

    Novel Insights Into the Microenvironment of Hodgkin Lymphoma

    • Tomohiro Aoki
  • 12:55–13:10

    Abstract T046: Functional characterization of STAT6 mutations as oncogenic drivers in classical Hodgkin lymphoma (cHL)

    • Luisa Tasselli
  • 13:10–13:25

    Abstract T047: Artificial intelligence predicts EBV status and reveals prognostic morphology phenotypes in advanced-stage classic Hodgkin lymphoma

    • Hishan Tharmaseelan

13:45 – 15:15

Room: Großer Saal

Satellite Symposium (by Takeda Oncology) From Evidence to Experience: How Long-Term and Real-World Data for ADCETRIS® (brentuximab vedotin) May Inform Frontline Practice in Advanced Hodgkin Lymphoma

  • Bastian von Tresckow
  • 13:45–13:50

    Welcome and Introductions

    • Bastian von Tresckow
  • 13:50–14:10

    Enhancing Frontline Management in Advanced HL with BrECADD

    • Otavio Baiocchi
  • 14:10–14:30

    Advancing HL Control and Fertility Preservation with BrECADD

    • Eldad Dann
  • 14:30–14:50

    Optimizing Care in High-Risk HL with A+AVD

    • Cathy Burton
  • 14:50–15:10

    Engage with the Experts (Q&A)

  • 15:10–15:15

    Meeting close

    • Bastian von Tresckow

15:30 – 17:00

Room: Großer Saal

Scientific Session Living Beyond Lymphoma

  • Max Büttner
  • Alexander Fosså
  • 15:30–15:50

    Evaluating Late Effects of Contemporary Treatments - Competing Risks & Novel Approaches

    • Caroline Dietrich
  • 15:50–16:10

    Uncertainties with Anti-PD1 & irAE in the First-Line Setting

    • Paul J. Bröckelmann
  • 16:10–16:30

    In Conversation with GHSG Patient Representatives: Building a Bridge Between Cancer Treatment and Everyday Life – Challenges After Lymphoma

    • Karolin Behringer
    • GHSG patient representatives
  • 16:30–16:45

    Abstract T092: Patients with a history of Hodgkin lymphoma have lower quality of life than matched comparators regardless of time elapsed since diagnosis

    • Peter Kamper
  • 16:45–17:00

    Abstract T093: The MyHodgkin MyHealth App: patient-derived data for tracking Hodgkin Lymphoma survivorship

    • Nicole Wong Doo

17:00 – 18:30

Room: Großer Saal

Scientific Session Advanced Stages

  • Philippe Armand
  • Graham Collins
  • Mark Hertzberg
  • 17:00–17:20

    Unmet Needs and Future Perspectives with BrECADD: Improving Outcomes of HD21

    • Justin Ferdinandus
  • 17:20–17:40

    Unmet Needs and Future Perspectives with Nivo-AVD: Unanswered Questions from SWOG S1826

    • Alex Herrera
  • 17:40–17:55

    Abstract T001: CHOP/miniCHOP And Tislelizumab in EldeRly patients with classical Hodgkin Lymphoma (cHL). A report of the phase II CATER-HL trial (HD12) from the Australasian Lymphoma and Leukaemia Group (ALLG)

    • Tara Cochrane
  • 17:55–18:10

    Abstract T002: Simplified Geriatric Assessment (sGA) in Older Patients With Classical Hodgkin Lymphoma (cHL): The Prospective ELDHL Project of the Fondazione Italiana Linfomi (FIL)

    • Vittorio Ruggero Zilioli
  • 18:10–18:25

    Abstract T003: Durable Remissions and Late Immune-Related Toxicities After Frontline Pembrolizumab + AVD in Classic Hodgkin Lymphoma

    • Ryan Lynch

ISHL14 Final Program

ISHL14 Final Program

Save the date

Save the event to your calendar

ISHL14: Program at a Glance

ISHL14: Program at a Glance

Archive

You can explore the ISHL13 program to get an impression of the broad spectrum and diversity of the congress.